URB937

URB937 is an orally active and peripherally restricted FAAH inhibitor (IC50=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) [1].

Product Specifications

CAS Number

[1357160-72-5]

Product Name Alternative

Nanchangmycin A

UNSPSC

12352005

Hazard Statement

H317, H319

Target

FAAH

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/urb937.html

Purity

99.85

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(OC1=CC(C2=CC=CC(C(N)=O)=C2)=C(O)C=C1)NC3CCCCC3

Molecular Formula

C20H22N2O4

Molecular Weight

354.40

Precautions

H317, H319

References & Citations

[1]Jason R Clapper, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010 Oct;13 (10) :1265-70.|[2]Valentina Vozella, et al. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor, in rats. J Pharm Pharmacol. 2019 Dec;71 (12) :1762-1773.|[3]G Moreno-Sanz, et al. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier. Br J Pharmacol. 2012 Dec;167 (8) :1620-8.|[4]Rui Li, et al. The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model. Inflammation. 2017 Aug;40 (4) :1254-1263.